Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218010 | 0.72 | CHRNA7 (0.78) | CHRM1CHRM3CHRM2CHRNA7HTR3E | |
| SCHEMBL3216388 | 0.72 | CHRNA7 (0.78) | CHRM1CHRM3CHRM2CHRNA7HTR3E | |
| SCHEMBL3225472 | 0.72 | CHRNA7 (0.78) | CHRM1CHRM3CHRM2CHRNA7HTR3E | |
| SCHEMBL9706330 | 0.71 | CHRNA7 (0.60) | CHRM1CHRM3CHRM2CHRNA7HTR3E | |
| Hydrochloric Acid SCHEMBL18704540 | 0.71 | CHRNA7 (0.76) | CHRM1CHRM3CHRM2CHRNA7HTR3E | |
| Hydrochloric Acid SCHEMBL7278119 | 0.71 | CHRNA7 (0.76) | CHRM1CHRM3CHRM2CHRNA7HTR3E | |
| SCHEMBL9672698 | 0.69 | CHRM1 (0.51) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL9905800 | 0.69 | CHRM1 (0.59) | CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL7266048 | 0.69 | CTSL (0.52) | CHRNA7CYP2D6 | |
| SCHEMBL372943 | 0.68 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558610-B1 | SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7179818-B2 | Substituted aminoquinuclidine compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20040110789-A1 | Substituted aminoquinuclidine compounds | BOYD ROBERT E (US) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110789-A1 | Substituted aminoquinuclidine compounds | OPRD1, OPRK1, OPRM1 | CHRM1 220/4885CHRM3 136/4885CHRM5 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.